Pluristem Therapeutics, Inc.
(NASDAQ : PSTI)

( )
PSTI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.36%352.430.0%$5529.05m
BNTXBioNTech SE -2.97%351.740.0%$1554.09m
NVAXNovavax, Inc. 7.56%208.6378.2%$1149.83m
AMGNAmgen, Inc. -2.26%198.881.4%$591.30m
LGVNLongeveron Inc. 0.04%26.260.0%$511.78m
GILDGilead Sciences, Inc. -2.44%68.931.0%$497.91m
REGNRegeneron Pharmaceuticals, Inc. -2.73%636.532.7%$490.45m
VRTXVertex Pharmaceuticals, Inc. -1.67%186.941.9%$375.32m
SNSSSunesis Pharmaceuticals, Inc. 0.88%4.610.7%$322.26m
ILMNIllumina, Inc. -1.48%365.333.3%$311.28m
OCGNOcugen, Inc. -1.40%6.340.0%$293.70m
BIIBBiogen, Inc. -0.16%235.741.8%$289.61m
EXASEXACT Sciences Corp. -1.39%85.3718.0%$167.68m
INCYIncyte Corp. -3.77%67.722.4%$165.57m
BMRNBioMarin Pharmaceutical, Inc. -1.27%86.294.2%$144.64m

Company Profile

Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.